Mankind Pharma Expands Regional Presence with New Office Inauguration in Hyderabad

Date:

Share post:

Mankind Pharma, one of India’s leading pharmaceutical companies, has officially inaugurated its brand-new regional office in Hyderabad, marking a significant milestone in its regional growth strategy. The expansion reflects the company’s commitment to focusing on innovation, accelerating growth, and strengthening its healthcare ecosystem across Telangana and Andhra Pradesh.

The official opening was commemorated with a traditional poojaceremony held on July 30 at the new facility, located on the 2nd Floor of Roxana Towers in Begumpet, Hyderabad. The inauguration event brought together leadership and team members to celebrate the company’s continued expansion.

Designed to serve as a vital operational and strategic center, the new Hyderabad office is set to become a vibrant hub for collaboration, operational excellence, and high-impact healthcare initiatives. By establishing a direct, local presence in Begumpet, Mankind Pharma aims to build deeper partnerships with local healthcare providers, distributors, and community stakeholders throughout the region.

Speaking on the milestone, Ramesh Kumar shared his enthusiasm for the company’s trajectory, noting that the new regional office underscores Mankind Pharma’s ongoing mission to improve access to quality healthcare. The expansion aligns with Mankind Pharma’s broader corporate philosophy”Serving Life” and positions the brand to deliver enhanced healthcare solutions to patients across southern India.

With this new strategic hub, Mankind Pharma reinforces its dedication to operational growth while continuing to build a healthier tomorrow.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Strategic Acquisition of U.K.-Based Estima Scientific

EVERSANA®, a leading global provider of modern, AI-powered commercial services for the biopharmaceutical industry, today announced the acquisition...

NPPA Slashes MRP on 543 Brands of Anti-Cancer Medicines; Revised Prices Effective November 9, 2026

In a major step toward making oncology therapies affordable and accessible, the National Pharmaceutical Pricing Authority (NPPA), under...

Cipla’s U.S. Subsidiary InvaGen Pharmaceuticals Successfully Concludes USFDA cGMP Inspection with Zero Form 483 Observations

Cipla Limited  announced that a routine current Good Manufacturing Practices (cGMP) inspection conducted by the United States Food and...

Cipla Reports Q2 FY27 Financial Results: Consolidated Net Profit Plunges 35% to ₹878 Crore on North America Drag; India Business Grows 12%

Cipla Limited today announced its consolidated financial results for the second quarter ended September 30, 2026 (Q2 FY27), reporting...